Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
50

Summary

Conditions
  • Fallopian Tube Cancer
  • Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
  • Bladder Cancer
  • Colo-rectal Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Triple -Negative Breast Cancer
  • Head and Neck Cancer Squamous Cell Carcinoma
  • Melanoma
  • Non -Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreas Cancer
  • Renal Cell Carcinoma
Type
Interventional
Phase
Phase 1
Design
Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent,...

This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent, loss to follow-up, or death, whichever occurs first. The study will include a Screening Period (of up to 21 days), a Treatment Period (with cycles of 3 weeks for a Q3W dosing regimen), and a Follow-up Period (approximately every 12 week visits) for up to 1 year after treatment discontinuation

Tracking Information

NCT #
NCT03621982
Collaborators
Not Provided
Investigators
Not Provided